David Nierengarten
Stock Analyst at Wedbush
(3.60)
# 776
Out of 4,784 analysts
214
Total ratings
38.86%
Success rate
8.35%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $2.20 | +400.00% | 3 | Mar 27, 2025 | |
| IMNM Immunome | Reiterates: Outperform | $33 | $6.99 | +372.10% | 6 | Mar 20, 2025 | |
| STRO Sutro Biopharma | Downgrades: Neutral | $8 → $2 | $0.74 | +171.33% | 7 | Mar 14, 2025 | |
| FATE Fate Therapeutics | Reiterates: Neutral | $5 | $0.85 | +488.72% | 15 | Mar 6, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Outperform | $31 | $13.40 | +131.34% | 2 | Feb 12, 2025 | |
| SWTX SpringWorks Therapeutics | Reiterates: Outperform | $77 | $47.41 | +62.41% | 6 | Feb 12, 2025 | |
| ANAB AnaptysBio | Maintains: Outperform | $40 | $18.95 | +111.08% | 13 | Feb 7, 2025 | |
| BPMC Blueprint Medicines | Reiterates: Outperform | $135 → $124 | $88.72 | +39.77% | 3 | Jan 13, 2025 | |
| APGE Apogee Therapeutics | Maintains: Outperform | $87 → $90 | $39.72 | +126.59% | 3 | Dec 2, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Outperform | $40 → $47 | $32.84 | +43.12% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $8.50 | -29.41% | 3 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 | $8.07 | +73.48% | 8 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $1.82 | +174.73% | 7 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $0.92 | +1,530.08% | 6 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $99 → $115 | $73.05 | +57.43% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $4.81 | +378.17% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $6.14 | +225.73% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $12.50 | +220.00% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $17.94 | +150.84% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.35 | +640.74% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $3.16 | +469.62% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $52.36 | +8.86% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.43 | +1,068.77% | 8 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $519 → $560 | $589.15 | -4.95% | 17 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $23.09 | +47.25% | 2 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $4.95 | +1.01% | 8 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $1.32 | +51.52% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $6.48 | +54.32% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $0.75 | +1,361.02% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $36 | $11.23 | +220.57% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $1.99 | +503.02% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $22.21 | +156.64% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $34 | $4.08 | +723.53% | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $7 | $0.38 | +1,744.53% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $2.93 | +16,964.85% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 | $6.32 | +422.15% | 2 | Oct 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $4.16 | +1,342.31% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $53 → $46 | $18.86 | +143.90% | 7 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $6.50 | +192.31% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $37.82 | +98.31% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.50 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.65 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $13.14 | - | 3 | Nov 20, 2017 |
Perspective Therapeutics
Mar 27, 2025
Reiterates: Outperform
Price Target: $11
Current: $2.20
Upside: +400.00%
Immunome
Mar 20, 2025
Reiterates: Outperform
Price Target: $33
Current: $6.99
Upside: +372.10%
Sutro Biopharma
Mar 14, 2025
Downgrades: Neutral
Price Target: $8 → $2
Current: $0.74
Upside: +171.33%
Fate Therapeutics
Mar 6, 2025
Reiterates: Neutral
Price Target: $5
Current: $0.85
Upside: +488.72%
Bicara Therapeutics
Feb 12, 2025
Reiterates: Outperform
Price Target: $31
Current: $13.40
Upside: +131.34%
SpringWorks Therapeutics
Feb 12, 2025
Reiterates: Outperform
Price Target: $77
Current: $47.41
Upside: +62.41%
AnaptysBio
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $18.95
Upside: +111.08%
Blueprint Medicines
Jan 13, 2025
Reiterates: Outperform
Price Target: $135 → $124
Current: $88.72
Upside: +39.77%
Apogee Therapeutics
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $39.72
Upside: +126.59%
Scholar Rock Holding
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $32.84
Upside: +43.12%
Nov 18, 2024
Reiterates: Outperform
Price Target: $6
Current: $8.50
Upside: -29.41%
Nov 18, 2024
Reiterates: Neutral
Price Target: $14
Current: $8.07
Upside: +73.48%
Oct 22, 2024
Reiterates: Outperform
Price Target: $5
Current: $1.82
Upside: +174.73%
Sep 30, 2024
Reiterates: Outperform
Price Target: $15
Current: $0.92
Upside: +1,530.08%
Sep 16, 2024
Maintains: Outperform
Price Target: $99 → $115
Current: $73.05
Upside: +57.43%
Sep 10, 2024
Reiterates: Outperform
Price Target: $23
Current: $4.81
Upside: +378.17%
Sep 10, 2024
Reiterates: Outperform
Price Target: $20
Current: $6.14
Upside: +225.73%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $12.50
Upside: +220.00%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $17.94
Upside: +150.84%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.35
Upside: +640.74%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $3.16
Upside: +469.62%
Aug 9, 2024
Reiterates: Outperform
Price Target: $57
Current: $52.36
Upside: +8.86%
Aug 8, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.43
Upside: +1,068.77%
Jul 26, 2024
Maintains: Outperform
Price Target: $519 → $560
Current: $589.15
Upside: -4.95%
Jul 23, 2024
Maintains: Outperform
Price Target: $30 → $34
Current: $23.09
Upside: +47.25%
Jun 27, 2024
Reiterates: Neutral
Price Target: $5
Current: $4.95
Upside: +1.01%
May 29, 2024
Downgrades: Neutral
Price Target: $8 → $2
Current: $1.32
Upside: +51.52%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $6.48
Upside: +54.32%
May 10, 2024
Reiterates: Outperform
Price Target: $11
Current: $0.75
Upside: +1,361.02%
May 10, 2024
Maintains: Outperform
Price Target: $34 → $36
Current: $11.23
Upside: +220.57%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $1.99
Upside: +503.02%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $22.21
Upside: +156.64%
Mar 19, 2024
Maintains: Neutral
Price Target: $60 → $34
Current: $4.08
Upside: +723.53%
Feb 29, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $0.38
Upside: +1,744.53%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $2.93
Upside: +16,964.85%
Oct 18, 2023
Reiterates: Outperform
Price Target: $33
Current: $6.32
Upside: +422.15%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $4.16
Upside: +1,342.31%
Jun 7, 2023
Upgrades: Neutral
Price Target: $53 → $46
Current: $18.86
Upside: +143.90%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $6.50
Upside: +192.31%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $37.82
Upside: +98.31%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.50
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $3.65
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $13.14
Upside: -